Predix Licenses S1P1 Modulators to Amgen
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 75 (Table of Contents)
Published: 6 Sep-2006
DOI: 10.3833/pdr.v2006.i75.462 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Predix Pharmaceuticals and Amgen entered into licensing agreement to develop orally available sphingosine-1-phosphate (S1P1) modulators for treating multiple autoimmune diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS